trial · primary record
MDNA11
Advanced Solid Tumor
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2028-10-20 |
| Primary endpoint | MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) |
| Registry ID | NCT05086692 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:35.565Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05086692
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.